On October 11, 2019 Vaccibody AS, a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies, appoints Dr Siri Torhaug as Chief Medical Officer (Press release, Vaccibody, OCT 11, 2019, View Source [SID1234540958]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Siri Torhaug is a medical doctor and certified clinical specialist in oncology. She has broad experience in clinical development and translational research within immune oncology, and has led clinical trials from early phase as well as pivotal phase II and III studies during her ten years at Oslo university hospital and Radiumhospitalet, one of Europe`s premier oncology hospital and research centers.
Having spent more than six years in leading pharmaceutical companies, Siri Torhaug brings invaluable experience to the team. She held local and Nordic medical leadership roles during her four years at Novartisincluding the role of Nordic medical disease lead for melanoma, lung, pipeline and immunooncology covering all aspects of early clinical trials in the Nordic countries. In addition, she was instrumentalto medical affairs activities and the overall strategy for Novartis’ immune-oncology portfolio in the Nordics. In 2017, Siri Torhaug moved to Astrazeneca where she was part of the Nordic Medical Oncology Leadership team, responsible for medical execution. Siri Torhaug’s knowledge and extensive experience in scientific andmedical affairs covering all relevant tumor areas, R&D and general management of cancer drug development will be of great value to Vaccibody when the company continues to develop and expand its clinical trial portfolio in the coming years.
"I am very pleased to welcome Siri Torhaug as Chief Medical Officer of Vaccibody. Siri is a seasoned leader and has deep experience within the immuno-oncology field across technologies including T cell therapy. Her valuable experience covers multiple aspects of clinical development from both the side of the clinician to several years of medical responsibility in big pharma. The Management team and I look forward to workingwith Siri and to continue Vaccibody’s successful journey", said Michael Engsig, CEO of Vaccibody. Siri Torhaug continues, "Vaccibody has such a strong momentum and is leading within the field of neoantigen cancer vaccines. I am very excited to join Vaccibody and become a part of this great organization."
Siri Torhaug will initiate her employment on January 1st, 2020.